Please wait while the formulary information is being retrieved.
Drug overview for CRYSVITA (burosumab-twza):
Generic name: burosumab-twza (bur-OH-sue-mab)
Drug class: Fibroblast Growth Factor 23 (FGF23) Inhibitors, Monoclon Ab
Therapeutic class: Endocrine
Burosumab is a recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody that binds to human fibroblast growth factor 23 (FGF23), a bone-derived hormone that regulates phosphate and vitamin D homeostasis.
No enhanced Uses information available for this drug.
Generic name: burosumab-twza (bur-OH-sue-mab)
Drug class: Fibroblast Growth Factor 23 (FGF23) Inhibitors, Monoclon Ab
Therapeutic class: Endocrine
Burosumab is a recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody that binds to human fibroblast growth factor 23 (FGF23), a bone-derived hormone that regulates phosphate and vitamin D homeostasis.
No enhanced Uses information available for this drug.
DRUG IMAGES
CRYSVITA 10 MG/ML VIAL
CRYSVITA 20 MG/ML VIAL
CRYSVITA 30 MG/ML VIAL
The following indications for CRYSVITA (burosumab-twza) have been approved by the FDA:
Indications:
FGF23-related hypophosphatemia in tumor-induced osteomalacia due to phosphaturic mesenchymal tumor
X-linked hypophosphatemic osteomalacia
Professional Synonyms:
Familial hypophosphatemia
Familial x-linked hypophosphatemic vitamin D refractory rickets
Fibroblast growth factor 23-related hypophosphatemia in tumor-induced osteomalacia due to PMT
Vitamin D resistant rickets
Vitamin D-resistant osteomalacia
Vitamin D-resistant rickets
Indications:
FGF23-related hypophosphatemia in tumor-induced osteomalacia due to phosphaturic mesenchymal tumor
X-linked hypophosphatemic osteomalacia
Professional Synonyms:
Familial hypophosphatemia
Familial x-linked hypophosphatemic vitamin D refractory rickets
Fibroblast growth factor 23-related hypophosphatemia in tumor-induced osteomalacia due to PMT
Vitamin D resistant rickets
Vitamin D-resistant osteomalacia
Vitamin D-resistant rickets
The following dosing information is available for CRYSVITA (burosumab-twza):
For the management of X-linked hypophosphatemia in adults, the recommended initial dosage of burosumab-twza is 1 mg/kg, rounded to the nearest 10 mg and not exceeding 90 mg, administered every 4 weeks.
Burosumab dosage in adults should be adjusted no more frequently than every 4 weeks based on fasting serum phosphorus concentrations.
Following initiation of burosumab therapy, fasting serum phosphorus concentrations should be measured monthly (with determinations made 2 weeks after a dose) for the first 3 months, then as clinically appropriate thereafter. Fasting serum phosphorus concentrations should be measured 2 weeks after dosage adjustments.
If the serum phosphorus concentration is within the normal range, burosumab should be continued at the same dosage.
If the serum phosphorus concentration exceeds the normal range, the next dose of burosumab should be withheld and the serum phosphorus concentration assessed again in 4 weeks. Once the serum phosphorus concentration is less than the normal range, therapy with burosumab may be reinitiated at a reduced dose of approximately one-half the initial dose (not exceeding 40 mg). (See Table 1.)
Table 1. Burosumab-twza Dose Reduction in Adults.
Previous Dose (mg) Reduced Dose for Reinitiation (mg) 40 20 50 20 60 30 70 30 80 or greater 40
For the management of X-linked hypophosphatemia in pediatric patients 1 year to less than 18 years of age, the recommended initial dosage of burosumab-twza is 0.8 mg/kg, rounded to the nearest 10 mg and not exceeding 90 mg, administered every 2 weeks. The minimum initial dose is 10 mg.
Burosumab dosage in pediatric patients should be adjusted no more frequently than every 4 weeks to maintain fasting serum phosphorus concentrations within the reference range for age.
Following initiation of burosumab therapy, fasting serum phosphorus concentrations should be measured every 4 weeks for the first 3 months, then as clinically appropriate thereafter. Fasting serum phosphorus concentrations should be measured 4 weeks after dosage adjustments.
If the serum phosphorus concentration exceeds the lower limit of the reference range for age but is below 5 mg/dL, burosumab should be continued at the same dosage.
If the serum phosphorus concentration is below the reference range for age, the dose may be increased in a stepwise manner, up to approximately 2 mg/kg (not exceeding 90 mg). (See Table 2.)
Table 2. Burosumab-twza Stepwise Dose Increases Based on Body Weight in Pediatric Patients 1 Year of Age or Older.
Body Weight (kg) Initial Dose (mg) Total Dose of Total Dose of First Stepwise Second Stepwise Dose Increase Dose Increase (mg) (mg) 10-14 10 15 20 15-18 10 20 30 19-31 20 30 40 32-43 30 40 60 44-56 40 60 80 57-68 50 70 90 69-80 60 90 Not applicable 81-93 70 90 Not applicable 94-105 80 90 Not applicable 106 or greater 90 Not applicable Not applicable
If the serum phosphorus concentration exceeds 5 mg/dL, the next dose of burosumab should be withheld and the serum phosphorus concentration assessed again in 4 weeks. Once the serum phosphorus concentration is less than the reference range for age, therapy with burosumab may be reinitiated at a reduced dose. (See Table 3.) The serum phosphorus concentration must be less than the reference range for age for reinitiation of the drug.
If the concentration remains less than the reference range for age at 4 weeks after reinitiation at a reduced dose, the dosage can be increased. (See Table 2.)
Table 3. Burosumab-twza Dose Reduction in Pediatric Patients 1 Year of Age or Older.
Previous Dose (mg) Reduced Dose for Reinitiation (mg) 10 5 15 10 20 10 30 10 40 20 50 20 60 30 70 30 80 40 90 40
Burosumab dosage in adults should be adjusted no more frequently than every 4 weeks based on fasting serum phosphorus concentrations.
Following initiation of burosumab therapy, fasting serum phosphorus concentrations should be measured monthly (with determinations made 2 weeks after a dose) for the first 3 months, then as clinically appropriate thereafter. Fasting serum phosphorus concentrations should be measured 2 weeks after dosage adjustments.
If the serum phosphorus concentration is within the normal range, burosumab should be continued at the same dosage.
If the serum phosphorus concentration exceeds the normal range, the next dose of burosumab should be withheld and the serum phosphorus concentration assessed again in 4 weeks. Once the serum phosphorus concentration is less than the normal range, therapy with burosumab may be reinitiated at a reduced dose of approximately one-half the initial dose (not exceeding 40 mg). (See Table 1.)
Table 1. Burosumab-twza Dose Reduction in Adults.
Previous Dose (mg) Reduced Dose for Reinitiation (mg) 40 20 50 20 60 30 70 30 80 or greater 40
For the management of X-linked hypophosphatemia in pediatric patients 1 year to less than 18 years of age, the recommended initial dosage of burosumab-twza is 0.8 mg/kg, rounded to the nearest 10 mg and not exceeding 90 mg, administered every 2 weeks. The minimum initial dose is 10 mg.
Burosumab dosage in pediatric patients should be adjusted no more frequently than every 4 weeks to maintain fasting serum phosphorus concentrations within the reference range for age.
Following initiation of burosumab therapy, fasting serum phosphorus concentrations should be measured every 4 weeks for the first 3 months, then as clinically appropriate thereafter. Fasting serum phosphorus concentrations should be measured 4 weeks after dosage adjustments.
If the serum phosphorus concentration exceeds the lower limit of the reference range for age but is below 5 mg/dL, burosumab should be continued at the same dosage.
If the serum phosphorus concentration is below the reference range for age, the dose may be increased in a stepwise manner, up to approximately 2 mg/kg (not exceeding 90 mg). (See Table 2.)
Table 2. Burosumab-twza Stepwise Dose Increases Based on Body Weight in Pediatric Patients 1 Year of Age or Older.
Body Weight (kg) Initial Dose (mg) Total Dose of Total Dose of First Stepwise Second Stepwise Dose Increase Dose Increase (mg) (mg) 10-14 10 15 20 15-18 10 20 30 19-31 20 30 40 32-43 30 40 60 44-56 40 60 80 57-68 50 70 90 69-80 60 90 Not applicable 81-93 70 90 Not applicable 94-105 80 90 Not applicable 106 or greater 90 Not applicable Not applicable
If the serum phosphorus concentration exceeds 5 mg/dL, the next dose of burosumab should be withheld and the serum phosphorus concentration assessed again in 4 weeks. Once the serum phosphorus concentration is less than the reference range for age, therapy with burosumab may be reinitiated at a reduced dose. (See Table 3.) The serum phosphorus concentration must be less than the reference range for age for reinitiation of the drug.
If the concentration remains less than the reference range for age at 4 weeks after reinitiation at a reduced dose, the dosage can be increased. (See Table 2.)
Table 3. Burosumab-twza Dose Reduction in Pediatric Patients 1 Year of Age or Older.
Previous Dose (mg) Reduced Dose for Reinitiation (mg) 10 5 15 10 20 10 30 10 40 20 50 20 60 30 70 30 80 40 90 40
Burosumab-twza is administered by subcutaneous injection. The drug should be administered by a clinician. Burosumab-twza injection must be stored at 2-8degreesC and kept in the original carton for protection from light until time of use.
Because burosumab-twza injection contains no preservatives, vials of the drug are intended for single dose only; unused portions remaining in the vial should be discarded. Burosumab-twza injection should be inspected visually prior to administration. Burosumab-twza injection is a clear to slightly opalescent, colorless to pale brown-yellow solution.
If the solution is discolored or cloudy or if any particles or foreign particulate matter is present, the drug must not be administered. Subcutaneous injections should be made into the upper arms, upper thighs, buttocks, or any quadrant of the abdomen; injection sites should be rotated, with each injection administered at a different anatomic location than the previous injection. Injections should not be made into moles, scars, or areas where the skin is tender, bruised, erythematous, hard, or not intact.
No more than 1.5 mL of burosumab-twza solution should be injected subcutaneously at any one site; if the injection volume exceeds 1.5 mL, the total volume of the dose should be divided and administered at 2 separate injection sites. If a dose of burosumab-twza is missed, the missed dose should be administered as soon as possible at the patient's usual dose.
Because burosumab-twza injection contains no preservatives, vials of the drug are intended for single dose only; unused portions remaining in the vial should be discarded. Burosumab-twza injection should be inspected visually prior to administration. Burosumab-twza injection is a clear to slightly opalescent, colorless to pale brown-yellow solution.
If the solution is discolored or cloudy or if any particles or foreign particulate matter is present, the drug must not be administered. Subcutaneous injections should be made into the upper arms, upper thighs, buttocks, or any quadrant of the abdomen; injection sites should be rotated, with each injection administered at a different anatomic location than the previous injection. Injections should not be made into moles, scars, or areas where the skin is tender, bruised, erythematous, hard, or not intact.
No more than 1.5 mL of burosumab-twza solution should be injected subcutaneously at any one site; if the injection volume exceeds 1.5 mL, the total volume of the dose should be divided and administered at 2 separate injection sites. If a dose of burosumab-twza is missed, the missed dose should be administered as soon as possible at the patient's usual dose.
No dosing information available.
No generic dosing information available.
The following drug interaction information is available for CRYSVITA (burosumab-twza):
There are 1 contraindications.
These drug combinations generally should not be dispensed or administered to the same patient. A manufacturer label warning that indicates the contraindication warrants inclusion of a drug combination in this category, regardless of clinical evidence or lack of clinical evidence to support the contraindication.
| Drug Interaction | Drug Names |
|---|---|
| Burosumab/Oral Phosphates; Active Vitamin D Analogs SEVERITY LEVEL: 1-Contraindicated Drug Combination: This drug combination is contraindicated and generally should not be dispensed or administered to the same patient. MECHANISM OF ACTION: Both burosumab and phosphates or vitamin D may increase serum phosphate levels. This combination may lead to greater increases in serum phosphate than anticipated. CLINICAL EFFECTS: The combination of burosumab with oral phosphates or active vitamin D analogs may result in hyperphosphatemia and may increase the risk of nephrocalcinosis.(1) PREDISPOSING FACTORS: Patients with renal impairment have alterations in mineral metabolism that may increase the risk of hyperphosphatemia.(1) PATIENT MANAGEMENT: The concomitant use of burosumab with oral phosphates or active vitamin D analogs is contraindicated. Discontinue oral phosphate and/or active vitamin D analogs one week before starting burosumab.(1) DISCUSSION: Burosumab restores dysfunctional renal phosphate reabsorption and renal production of 1,25-dihydroxyvitamin D to treat X-linked hypophosphatemia. Additional oral phosphates and/or active vitamin D analogs may raise serum phosphate higher than anticipated. |
CALCITRIOL, CALCITRIOL IN ALMOND OIL, DOXERCALCIFEROL, HECTOROL, K-PHOS NO.2, K-PHOS ORIGINAL, MB CAPS, ME-NAPHOS-MB-HYO 1, PARICALCITOL, POTASSIUM PHOSPHATE, RAYALDEE, ROCALTROL, SODIUM PHOSPHATE DIBASIC, URELLE, URETRON D-S, URIMAR-T, URNEVA, URO-MP, URO-SP, UROGESIC-BLUE, UROQID-ACID NO.2, URYL, ZEMPLAR |
There are 0 severe interactions.
There are 0 moderate interactions.
The following contraindication information is available for CRYSVITA (burosumab-twza):
Drug contraindication overview.
Use of burosumab is contraindicated in combination with oral phosphate supplements and activated vitamin D analogs (e.g., calcitriol) and in patients with severe renal impairment or end-stage renal disease. The drug should not be initiated if serum phosphorus concentration is within or exceeds the normal range for age.
Use of burosumab is contraindicated in combination with oral phosphate supplements and activated vitamin D analogs (e.g., calcitriol) and in patients with severe renal impairment or end-stage renal disease. The drug should not be initiated if serum phosphorus concentration is within or exceeds the normal range for age.
There are 2 contraindications.
Absolute contraindication.
| Contraindication List |
|---|
| Chronic kidney disease stage 4 (severe) GFR 15-29 ml/min |
| Chronic kidney disease stage 5 (failure) GFr<15 ml/min |
There are 1 severe contraindications.
Adequate patient monitoring is recommended for safer drug use.
| Severe List |
|---|
| Kidney disease with likely reduction in glomerular filtration rate (GFr) |
There are 0 moderate contraindications.
The following adverse reaction information is available for CRYSVITA (burosumab-twza):
Adverse reaction overview.
Adverse effects reported in more than 10% of pediatric patients receiving burosumab-twza in clinical studies include headache, injection site reaction, vomiting, pyrexia, pain in extremity, decreased vitamin D concentration, rash, toothache, myalgia, tooth abscess, and dizziness. Adverse effects reported in more than 5% of adults receiving burosumab-twza in a clinical study and in at least 2 more burosumab-treated patients than placebo recipients include back pain, headache, tooth infection, new or worsening restless legs syndrome, decreased vitamin D concentration, dizziness, constipation, and hyperphosphatemia. In phase 2 and 3 studies of burosumab-twza in adults with X-linked hypophosphatemia, 3.4%
of patients underwent spinal surgery. Spinal stenosis is prevalent in adults with X-linked hypophosphatemia, and spinal cord compression also has been reported. Most cases requiring spinal surgery during these studies appeared to involve progression of preexisting spinal stenosis, but it is unknown whether burosumab exacerbates spinal stenosis or spinal cord compression.
Adverse effects reported in more than 10% of pediatric patients receiving burosumab-twza in clinical studies include headache, injection site reaction, vomiting, pyrexia, pain in extremity, decreased vitamin D concentration, rash, toothache, myalgia, tooth abscess, and dizziness. Adverse effects reported in more than 5% of adults receiving burosumab-twza in a clinical study and in at least 2 more burosumab-treated patients than placebo recipients include back pain, headache, tooth infection, new or worsening restless legs syndrome, decreased vitamin D concentration, dizziness, constipation, and hyperphosphatemia. In phase 2 and 3 studies of burosumab-twza in adults with X-linked hypophosphatemia, 3.4%
of patients underwent spinal surgery. Spinal stenosis is prevalent in adults with X-linked hypophosphatemia, and spinal cord compression also has been reported. Most cases requiring spinal surgery during these studies appeared to involve progression of preexisting spinal stenosis, but it is unknown whether burosumab exacerbates spinal stenosis or spinal cord compression.
There are 5 severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Vitamin D deficiency |
Dental abscess Hyperphosphatemia Hypersensitivity drug reaction |
| Rare/Very Rare |
|---|
|
Nephrocalcinosis |
There are 16 less severe adverse reactions.
| More Frequent | Less Frequent |
|---|---|
|
Back pain Constipation Cough Dental caries Dizziness Fever Headache disorder Injection site sequelae Muscle spasm Pain Pain in extremities Restless leg syndrome Toothache Vomiting |
Skin rash Urticaria |
| Rare/Very Rare |
|---|
| None. |
The following precautions are available for CRYSVITA (burosumab-twza):
Safety and efficacy of burosumab have not been established in pediatric patients younger than 1 year of age. Safety and efficacy of burosumab have been established in 2 open-label studies in 52 children 5-12 years of age and 13 children 1-4 years of age with X-linked hypophosphatemia. (See Rickets in Pediatric Patients under Uses: X-linked Hypophosphatemia.) Efficacy in adolescents with X-linked hypophosphatemia has been extrapolated from studies conducted in pediatric patients younger than 13 years of age, while dosage in adolescents was derived using modeling and simulation of both adult and pediatric pharmacokinetic and pharmacodynamic data. No substantial age-related differences in the pharmacokinetics of burosumab have been observed.
Contraindicated
Severe Precaution
Management or Monitoring Precaution
Contraindicated
| None |
Severe Precaution
| None |
Management or Monitoring Precaution
| None |
Data regarding use of burosumab in pregnant women are lacking. Burosumab crosses the placenta in monkeys. Reproduction studies in monkeys without X-linked hypophosphatemia have revealed no evidence of teratogenicity with IV burosumab-twza at exposure levels up to 64 times the exposure at the recommended adult dosage of 1 mg/kg every 4 weeks.
Increases in late fetal loss and preterm births were observed but were not thought to indicate clinical risk since these effects were observed at the highest exposure and were accompanied by maternal hyperphosphatemia and placental mineralization. No adverse effects on prenatal and postnatal growth, including offspring survival, were observed. If burosumab is used during pregnancy, serum phosphorus concentrations should be monitored throughout pregnancy.
Pregnancies in patients receiving burosumab-twza should be reported to the Kyowa Kirin, Inc. Adverse Event reporting line at 888-756-8657.
Increases in late fetal loss and preterm births were observed but were not thought to indicate clinical risk since these effects were observed at the highest exposure and were accompanied by maternal hyperphosphatemia and placental mineralization. No adverse effects on prenatal and postnatal growth, including offspring survival, were observed. If burosumab is used during pregnancy, serum phosphorus concentrations should be monitored throughout pregnancy.
Pregnancies in patients receiving burosumab-twza should be reported to the Kyowa Kirin, Inc. Adverse Event reporting line at 888-756-8657.
It is not known whether burosumab is distributed into human milk. Effects of the drug on the breast-fed infant (e.g., resulting from local GI exposure or limited systemic exposure) or milk production also are not known. The benefits of breast-feeding and the woman's clinical need for burosumab should be considered along with any potential adverse effects on the breast-fed infant from the drug or from the underlying maternal condition.
Clinical trials of burosumab did not include sufficient numbers of patients 65 years of age or older to determine whether geriatric patients respond differently than younger patients. While other clinical experience has not revealed age-related differences in response, dosage of burosumab generally should be selected carefully in geriatric patients, usually initiating therapy at the low end of the dosage range, because of the greater frequency of decreased hepatic, renal, and/or cardiac function and of concomitant disease and drug therapy observed in the elderly. No substantial age-related differences in the pharmacokinetics of burosumab have been observed.
The following prioritized warning is available for CRYSVITA (burosumab-twza):
No warning message for this drug.
No warning message for this drug.
The following icd codes are available for CRYSVITA (burosumab-twza)'s list of indications:
| FGf23-related hypophosphatemia in TIO due to PMT | |
| M83.8 | Other adult osteomalacia |
| X-linked hypophosphatemic osteomalacia | |
| E83.31 | Familial hypophosphatemia |
Formulary Reference Tool